Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06960889

A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients

This single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. Adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between January 2017 and December 2024 were consecutively enrolled. Patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Esophageal Cancer (EsC) Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Nanfang Hospital, Southern Medical University

Guangzhou, 510515, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Waiver of informed consent for deceased or lost-to-follow-up patients (January 2017-March 2024)
  • Voluntary signed informed consent from surviving patients who could be contacted
  • Treatment at Nanfang Hospital, Southern Medical University (January 2017-December 2024)
  • Received antitumor therapy for esophageal cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2

Exclusion criteria

  • Concurrent other malignancies
  • Patients deemed ineligible by investigators

Treatment and study plan

Radiotherapy

Other

Definitive radiotherapy or radiotherapy-based combined modality therapy

Immunotherapy

Drug

Immune checkpoint inhibitors as monotherapy or in combination with other therapies

surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines

Procedure

Radical esophagectomy with or without neoadjuvant/adjuvant therapy

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From the date of treatment initiation to the date of death from any cause,assessed up to 120 months.

    The length of time from the start of treatment until death from any cause, evaluating the long-term survival benefit of the combined therapy.

Secondary outcomes

  1. Pathologic Complete Response ( pCR )

    Time frame: Perioperative

    The absence of residual viable tumor cells in both the primary esophageal tumor and regional lymph nodes after completion of surgery, indicating a complete pathological response.

  2. Major Pathological Response Rate (MPR)

    Time frame: Perioperative

    The proportion of patients with ≤10% residual viable tumor cells in resected specimens

  3. Progression-Free Survival (PFS)

    Time frame: From treatment initiation to disease progression or death, assessed up to 100 months

    The duration from treatment start until radiologically confirmed disease progression (per RECIST v1.1) or death from any cause, evaluating therapeutic efficacy in delaying tumor growth.

Sponsors and collaborators

Lead sponsor

Nanfang Hospital, Southern Medical University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
May 7, 2025
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.